Stem cell-derived pancreatic islets are being studied as a rich transplantable source for insulin production, a therapeutic ...

Indeed, experimental combination drugs that pair GLP-1 agonists with compounds that raise levels of glucagon have recently ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

TUCSON, AZ / ACCESS Newswire / April 29, 2025 / Retatrutide, also known as LY3437943, is an innovative triple receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), ...

Drug-induced liver injury was reported in 1 asymptomatic patient in one of the once-daily danuglipron dose-optimization studies. Pfizer has made the decision to discontinue the clinical development ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

In addition to impaired insulin secretion, type 2 diabetic patients also have elevated levels of glucagon, which worsens hyperglycemia by increasing glucose production by the liver. Type 2 ...

Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...